Welcome to our dedicated page for Dianthus Therapeutics SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dianthus Therapeutics filings document the regulatory record of a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. The company’s 8-K reports furnish operating and financial results, corporate presentations, clinical-program disclosures for claseprubart, FDA feedback on trial screening and safety-risk language, and updates tied to programs in neuromuscular and rheumatology indications.
Other filings cover capital-structure and governance matters, including common stock listed on the Nasdaq Capital Market, underwritten public offering agreements, pre-funded warrant terms, shareholder voting matters, proxy disclosure, material agreements, and equity-compensation actions. These records also describe risk-factor and forward-looking disclosure around clinical development, regulatory interactions, financing needs and public-company governance.
Dianthus Therapeutics SVP and General Counsel Adam M. Veness reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 30,000 shares of common stock at a strike price of $17.88 per share, then sold 30,000 shares in open-market trades at weighted average prices of $80.34 and $81.38 per share. These sales were executed under a Rule 10b5-1 trading plan. Following the transactions, he held no shares of common stock directly but retained 80,000 stock options that continue to vest over four years beginning January 1, 2024.
Dianthus Therapeutics posted an updated corporate presentation highlighting new clinical and strategic data for its autoimmune pipeline. The company reported an interim responder analysis from Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy, where 75% of the first 40 participants who completed Part A were confirmed responders based on adjusted INCAT improvement. The presentation also detailed Phase 2 MaGic trial results in generalized myasthenia gravis, showing statistically significant and clinically meaningful improvements versus placebo across multiple endpoints, including MG-ADL, QMG, MGC, MG-QoL-15r and Minimal Symptom Expression at Week 13 for the 300mg/2mL dose. Claseprubart was generally well tolerated in Phase 1 and 2 with no signal of encapsulated bacterial infections or clinical symptoms of drug-induced lupus, supporting a target profile without a boxed warning or REMS. Dianthus additionally highlighted DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor in Phase 1, and reported cash, cash equivalents and investments of about $1.2B as of March 31, 2026 with runway expected into 2030.
Dianthus Therapeutics EVP and Head of R&D Simrat Randhawa reported option exercises and share sales in common stock. On June 1, 2026, Randhawa exercised stock options for a total of 26,530 shares of common stock at exercise prices between $8.44 and $22.07 per share.
On the same date, Randhawa sold 26,530 shares of common stock in open-market transactions at weighted average prices reported as $89.72, $90.72, and $91.37 per share, with actual trade prices ranging from $89.17 to $91.96. The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, indicating the transactions were scheduled in advance.
DNTH filing of a Form 144 notifies the proposed sale of 26,530 shares of Common Stock via an exercise of stock options on 06/01/2026. The filing lists 2467555.30 (amount) and a figure 54,666,233 in the securities section. It also discloses prior 10b5-1 sales: 33,830 shares on 03/12/2026 with 2756333.08 (amount).
Dianthus Therapeutics director Simon Read reported a grant of 6,090 stock options. These options give him the right to buy 6,090 shares of common stock at an exercise price of 89.63 per share and expire on May 21, 2036.
The award will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholders’ meeting, as long as he continues serving the company through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Dianthus Therapeutics director Steven J. Romano received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. According to the terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual meeting of stockholders, provided he continues serving the company through that vesting date.
Dianthus Therapeutics director Anne McGeorge received a grant of stock options, not a market purchase or sale. The award covers 6,090 options to buy common stock at an exercise price of $89.63 per share, expiring on May 21, 2036.
According to the terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, as long as she continues serving the company through that vesting date.
Dianthus Therapeutics director Alison Frances Lawton received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, she holds 6,090 stock options directly.
According to the grant terms, all shares underlying this option will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual meeting of stockholders, as long as she continues to serve the company through the vesting date.
Dianthus Therapeutics director Sujay Kango received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. Following this award, Kango holds 6,090 derivative securities in the form of these options.
According to the vesting terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided Kango continues to serve the company through that vesting date.